Clinical data from open-label daffodil™ study evaluating long-term safety of daybue® (trofinetide) in patients with rett syndrome published in med

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced that the journal med published results from the open-label study, daffodil™, evaluating the safety, tolerability and exploratory efficacy of daybue® (trofinetide) in girls ages two to four living with rett syndrome (n = 15). the long-term phase 2/3 study demonstrated daybue had a similar safety profile in children two to four years of age as that observed in individuals with rett syndrome five years of age an.
ACAD Ratings Summary
ACAD Quant Ranking